Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Modalis Therapeutics Corporation ( (JP:4883) ).
Modalis Therapeutics Corporation announced a change in its certified public accountants, with Alpha Audit Corporation set to replace KPMG AZSA LLC after the latter’s term ends on March 27, 2025. This decision, approved by the Audit and Supervisory Committee, aims to bring a fresh audit perspective, appropriate audit fees, and leverage Alpha Audit Corporation’s expertise and quality control, which may impact the company’s financial oversight and stakeholder confidence.
More about Modalis Therapeutics Corporation
Modalis Therapeutics Corporation is a company listed on the Tokyo Stock Exchange, specializing in the biotechnology industry. It focuses on developing innovative therapies and has a market focus that involves cutting-edge research and development in therapeutic modalities.
YTD Price Performance: -1.96%
Average Trading Volume: 6,590,179
Technical Sentiment Consensus Rating: Buy
Current Market Cap: Yen7.42B
See more data about 4883 stock on TipRanks’ Stock Analysis page.